The top three tumor immune products rank among the top 6 anticancer drugs
Recently, FiercePharma released 15 best-selling anticancer drugs in 2022. It is estimated that by 2022, 15 best-selling anticancer drugs will generate nearly $90 billion in sales, accounting for the total US pharmaceutical market in 2014. 1/4 of the value.
In this list, three PD-1/PD-L1 inhibitors belonging to tumor immunology (I-O) therapy ranked in the top six. However, there is some controversy about the pricing of these drugs. Today, global drug pricing is strictly controlled by regulators and payers to a certain extent.
The huge difference between the new best-selling anticancer drug prediction list and the version three years ago shows the rapid development of the anticancer drug industry. For example, Takeda's melanoma drug, Velcade, and Johnson & Johnson's oral anti-prostate cancer drug, Zytiga, have disappeared in the list of best-selling anticancer drugs in 2022. Both will face the threat of innovative drugs and generic drugs.
Although tumor immunotherapy is accelerating, nine of the 15 best-selling anticancer drugs in 2022 are monoclonal antibodies, three of which are from Roche. These drugs are also the first monoclonal antibody drugs that will face the challenge of biosimilar drugs in the next few years, but their brand strength still helps them maintain an important market position.
Revlimid
For the past 10 years since the market was launched, Revlimid has been an important sales force for Celgene, the most important product in the treatment of new blood medicine, the company's expected year of 2020. Sales will exceed $15 billion, and sales of lenalidomide by 2022 are expected to double.
Xinji Medicine has spent $1 billion to expand lenalidomide maintenance therapy for non-Hodgkin's lymphoma (NHL) subtypes and diffuse large B-cell lymphoma indications, but phase III clinical failure, after which the drug continues Treatment trial for follicular lymphoma. Xinji Medicine is still confident in the importance of lenalidomide, and believes that it will remain an important sales driver in 2020 and beyond.
Blunt Canulas,Blunt Cannulas,Blunt Tip Cannulas,Blunt Cannula Needle
Qingdao Beautiful Skin Biotechnology Co., Ltd , https://www.hafilleresthetic.com